 |
|
Genomics and Proteomics May Help Clinicians Individualize Cancer Treatment
M. J. Friedrich
JAMA. 2002;287:2931-2932.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
San Francisco—Analysis of the genetic mutations behind the transformation and growth of cancer cells provides information that is spurring the development of new and better ways to diagnose and treat cancer. But many researchers are also looking beyond the "blueprint for life" to proteins for insights the genome does not provide.
Proteomics, which includes analysis of protein interactions in a cell (JAMA. 2001;286:2211-2214), is a young field but one that is growing fast. By cataloging the many proteins in the body and discovering how they function in tissues, researchers hope to gain a better understanding of what goes wrong in the protein networks in cancer cells.
The first clinical applications of proteomics are being undertaken at the National Cancer Institute (NCI) in Bethesda, Md, and preliminary results involving patients with breast and ovarian cancer are provocative. But rather than replace genetic analysis, the hope . . . [Full Text of this Article]
|
